704 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ABBV AbbVie Inc. $95.37 $144.42B N/A
Article Searches
Top Stock Reports for Boeing, Lockheed Martin & Anthem http://www.zacks.com/research-daily/371422/top-stock-reports-for-boeing-lockheed-martin-anthem?cid=CS-ZC-FT-371422 Apr 05, 2019 - Top Stock Reports for Boeing, Lockheed Martin & Anthem
Novartis Resubmits BLA to FDA for Biosimilar of Neulasta http://www.zacks.com/stock/news/370752/novartis-resubmits-bla-to-fda-for-biosimilar-of-neulasta?cid=CS-ZC-FT-370752 Apr 04, 2019 - Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.
Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals http://www.zacks.com/stock/news/367176/pharma-stock-roundup-azn-inks-cancer-deal-abbv-nvs-others-get-drug-approvals?cid=CS-ZC-FT-367176 Mar 29, 2019 - AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.
Gilead & Galapagos Announce Positive Data on Arthritis Drug http://www.zacks.com/stock/news/366666/gilead-galapagos-announce-positive-data-on-arthritis-drug?cid=CS-ZC-FT-366666 Mar 29, 2019 - Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
2 Things Investors Are Missing About AbbVie https://www.fool.com/investing/2019/03/17/2-things-investors-are-missing-about-abbvie.aspx?source=iedfolrf0000001 Mar 17, 2019 - The big-pharma company could be in much better shape than you think.
Roche Receives EC Approval for Label Expansion of Hemlibra http://www.zacks.com/stock/news/359564/roche-receives-ec-approval-for-label-expansion-of-hemlibra?cid=CS-ZC-FT-359564 Mar 14, 2019 - Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
AbbVie, Inc. (ABBV) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript) https://seekingalpha.com/article/4248520-abbvie-inc-abbv-presents-barclays-global-healthcare-broker-conference-call-transcript?source=feed_sector_healthcare Mar 13, 2019 - AbbVie, Inc. (NYSE:ABBV) Barclays Global Healthcare Conference March 13, 2019, 10:15 ET Company Participants Robert Michael - SVP & CFO Michael Severino - Vice Chairman & President Conference
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC http://www.zacks.com/stock/news/358374/roches-rhhby-tecentriq-gets-ec-nod-for-first-line-nsclc?cid=CS-ZC-FT-358374 Mar 08, 2019 - Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice http://www.zacks.com/stock/news/357873/are-you-looking-for-a-high-growth-dividend-stock-abbvie-abbv-could-be-a-great-choice?cid=CS-ZC-FT-357873 Mar 06, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Here's Why Voyager Therapeutics Stock Rose as Much as 13% Today https://www.fool.com/investing/2019/03/04/heres-why-voyager-therapeutics-rose-as-much-as-13.aspx?source=iedfolrf0000001 Mar 04, 2019 - The gene therapy company saw another peer get gobbled up in an acquisition.

Pages: 12345678910...71

<<<Page 5>